Advancing NIH Research on the Health of Women: A 2021 Conference

NCI Clinical Trials in Gynecologic Cancer: A Changing Landscape

Robert S. Mannel, MD
Co-Chair of NRG Oncology
Director of OU Stephenson Cancer Center
October 20, 2021
A National Response to Address Gynecologic Malignancies

- 1971 – Gynecologic Oncology Group founded with support from the NCI
- Eleven founding institutions
- Includes gynecologic, radiation and medical oncology
- Rapid growth over next 40 years with over 300 member institutions nationally and internationally
- Set the worldwide standard for management of gynecologic malignancies
GOG – Total accrual first 40 years

Total Accrual
(Total 91,871 Patients)

- 1971 - 80: 8,508
- 1981 - 90: 15,675
- 1991 - 00: 26,020
- 2001 - 10: 41,668
GOG Phase III Accrual – Growth over the first 40 years

Phase III Accrual
(Total 40,795 Patients)

- 1971-80: 4,813
- 1981-90: 7,600
- 1991-00: 12,563
- 2001-10: 15,819
Population, Clinical, and Scientific Impact of National Cancer Institute-Sponsored Clinical Trial Network Treatment Studies


* Presenting Author:
  Associated Professor, Fred Hutchinson Cancer Research Center, Seattle
  Senior Biostatistician and Health Services Researcher, SWOG Cancer Research Network
Population Impact

- Overall, 128 trials showed overall survival favoring the experimental arm
- These trials are estimated to have generated gains of 14.0 million life-years to patients
- Federal investment cost per life year was previously estimated at $125/year in subset of trials*
- Projected estimates for 2025 and 2030 increase substantially (18.4 million and 23.4 million)

*Unger, LeBlanc, Blanke; JAMA Onc, 2017
Clinical Impact

- In total, 80.4% of trials influenced care recommendations in formal guidelines.
Creation of the NRG

NRG

GOG foundation

RTOG foundation

NSABP Foundation
Accrual to NCI GOG/NRG Phase I – III Trials
GOG Foundation Mission/Vision

Mission
To conduct clinical and translational research that improves the prevention of, and positively impacts women affected by, gynecologic malignancies.

Vision
To be the premier collaborative network for transformative research in gynecologic malignancies.
GOG Foundation

A home with an open-concept design and infrastructure to support collaborative efforts
The New GOG Foundation

- Mentor/Engage
  - Leadership development
  - Access to opportunities
  - Structured mentoring

- Science
  - Scientific priorities
  - Protocol development
  - Integrated portfolio
  - Meeting structure

- Organizational Development
  - Succession planning
    - Roles
    - Transparency

- Enable
  - New capabilities
  - Processes, systems, and tools

- Collaborate
  - Industry
    - NIH/NCI
    - ENGOT
    - SGO
    - Other
GOG Foundation Accrual

- Total 2018
- Total 2019
- Total 2020
- First Half 2021

- Partners Total
- NRG Total
Opportunities for NCI Gynecologic Cancer Clinical Trials

• Prioritize clinical research in gynecologic cancers on par with other disease sites
• Facilitate international collaboration – especially with new drugs and in rare diseases
• Facilitate real time data sharing
• Simplify layers of review to allow streamlined timelines
• Emphasize feasible research on interventions likely to be practice changing
• Support critical surgical, imaging and radiation therapy questions – trials which will not be funded by industry
• Restructure funding to adequately support trial costs